Doubling influenza vaccine production capacity and launching a rapid testing instrument
First written in FY2019. 3 of 10 entries say "Advanced", first in FY2021. Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1Decrease in influenza vaccine sales volumeAnnual report
「In addition, influenza vaccine sales volume fell below the previous year due to shifts in the timing of some shipments.」
Influenza vaccine sales volume, which had exceeded or remained at the previous year's level after production capacity was expanded, fell below the previous year in the current interim period due to shifts in the timing of some shipments. - FY2025-H1AdvancedAnnual report
「Influenza vaccine sales exceeded the prior year as a result of efforts to ship products earlier.」
Influenza vaccine sales exceeded the prior year as a result of efforts to ship products earlier. - FY2024-Q3Influenza vaccine shipments at the prior-year levelAnnual report
「In addition, sales of other test reagents were at the prior-year level, and influenza vaccine shipments also remained at the prior-year level.」
Influenza vaccine shipments, which had exceeded the prior year following the previous fiscal year's capacity expansion, were at the prior-year level this quarter. - FY2024-Q2Influenza vaccine shipments at the prior-year levelAnnual report
「In addition, sales of other test reagents exceeded the prior year, while influenza vaccine shipments were at the prior-year level.」
Influenza vaccine shipments, which had exceeded the prior year through the previous quarter, were at the prior-year level this quarter. - FY2023RestatedAnnual report
「Influenza vaccine shipments exceeded the previous year because production capacity had been expanded.」
This reconfirms that influenza vaccine shipments after the production capacity expansion exceeded the prior year. - FY2023-Q2AdvancedAnnual report
「Influenza vaccine shipments exceeded the previous year because production capacity had been expanded.」
The increase in influenza vaccine production capacity has been reflected in shipments exceeding the prior year, indicating progress in the capacity expansion measures. - FY2022-Q3RestatedAnnual report
「Meanwhile, influenza vaccine shipments were below the previous year because production volumes fell below the previous year, owing to the effects of factors including the growth characteristics of the vaccine production strain, in addition to shortages of production materials caused by the global increase in production of novel coronavirus vaccines.」
The situation in which influenza vaccine production volumes and shipments fell below the previous year owing to shortages of materials and other factors resulting from increased production of novel coronavirus vaccines is being reconfirmed. - FY2022-Q2Decrease in influenza vaccine shipmentsAnnual report
「Influenza vaccine shipments were below the previous year because production volumes fell below the previous year, owing to the effects of factors including the growth characteristics of the vaccine production strain, in addition to shortages of production materials caused by the global increase in production of novel coronavirus vaccines.」
Influenza vaccine production volumes and shipments fell below the previous year owing to shortages of production materials and other factors. - FY2021AdvancedAnnual report
「Major facility construction projects completed during the fiscal year included completion of a new building for manufacturing influenza vaccine bulk at the Company’s Gosen Facility and construction of a new hydroelectric power plant at the Omi Plant.」
In the Life Innovation field, a new building for manufacturing influenza vaccine bulk at the Gosen Business Center was completed during the fiscal year. - FY2019First statedAnnual report
「In addition to deciding to increase influenza vaccine production facilities to twice the current supply capacity, in October 2018 we newly launched the “QuickNavi Reader™” densitometry (optical density measurement) analyzer dedicated to the “QuickNavi™-Flu2” rapid influenza virus testing kit.」
A decision was made to double vaccine production capacity, and a dedicated analyzer for the rapid testing kit was newly launched in October 2018.